Skip to main content

Novartis Ag ADR(NVS-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low101.82
Day High103.60
Open:103.54
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Free Reports for Novartis Ag ADR

News for Novartis Ag ADR

Select a category then submit the form to load news
MarketBeat
Are Gene Therapy Stocks The Market's Next Big Winners?
Motley Fool
2 Dividend Stocks to Buy and Hold Forever
Motley Fool
Why Shares of Bicycle Therapeutics Were Rising on Monday
MarketBeat
AI 2.0 is Here: How to Invest in a Generational Opportunity
Newswire.ca
INNODEM NEUROSCIENCES SIGNS A STRATEGIC COMMERCIAL FRAMEWORK AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA INC.
Motley Fool
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Newswire.ca
Find Therapeutics Appoints Robert L. Glanzman, M.D., as Chief Medical Officer
Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
MarketBeat
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Motley Fool
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Motley Fool
Is Regeneron Stock a Buy Now?
OTOS Inc.
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar
Motley Fool
Could This Medicine Be the Next Winner for Novartis?
SYNDTGAM
Novartis plans Sandoz spinoff around Oct. 4, proposes share distribution
Motley Fool
2 Excellent Stocks to Buy and Hold Forever
Motley Fool
2 Top Biotech Stocks to Buy Right Now
Motley Fool
3 Unstoppable Dividend Stocks to Buy Right Now
Motley Fool
Is This Blue Chip Dividend Stock a Buy for Growth Investors?
Newswire.ca
Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer
Barchart
An Under the Radar Healthcare Stock to Add to Your Portfolio
Motley Fool
2 Surefire Stocks to Buy With $500
MarketBeat
7 Best Cancer Stocks to Invest in Now
Motley Fool
2 Stocks That Raised Their Guidance in July
MarketBeat
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
Motley Fool
Should Income Investors Buy This Blue Chip Stock?
MarketBeat
Can Novartis Move to New Highs and Sustain Them? 
Motley Fool
Why Novartis Stock Spiked Today
Motley Fool
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
Baystreet
CPI Due in Canada Next Week
MarketBeat
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Newswire.ca
PLUVICTO™ receives positive recommendations from CADTH and INESSS for progressive PSMA-positive metastatic castration-resistant prostate cancer
Motley Fool
Why Novartis Stock Slipped on Friday
More Novartis Ag ADR news

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.